CytoReason Cements Proof-of-Concept with Machine-Learning-Facilitated Biomarker Breakthrough in Anti-TNFα Treatment Failure in Inflammatory Bowel Disease. New Data Published in Gut

CytoReason’s proprietary technology demonstrates ability to
reconstruct hidden cellular signals, extrapolate one tissue to another
and identify immune system relationships capable of revealing new
biomarkers and potential new treatment targets for immune-related drugs.

TEL AVIV, Israel–(BUSINESS WIRE)–#PharmaNew
data published in the prestigious BMJ journal, Gut
, outlines the
role of a new technological platform approach that has revealed a new
blood-based biomarker that is 94% accurate in pretreatment
identification of anti-TNFα non-responders in inflammatory bowel disease
(IBD), accounting for approximately 30% of patients, confirming validity
of the approach.

The application of this platform led to the identification of the
TREM1-CCR2-CCL7 axis (which manages the movement of inflammatory
monocytes) and plasma cell abundance as accurate pretreatment markers of
anti-TNFα response in inflammatory bowel disease (IBD). The study
demonstrated TREM-1 expression in peripheral blood to be an accessible
and accurate predictor of non-response. The findings demonstrate the
platform’s ability to reconstruct previously lost cellular information
and isolate an easier to access blood-based biomarker.

The data showcases CytoReason’s ability to provide unique immune-system
insights and interpretation that generate new directions for enhanced
target identification, improved indication assessment, more effective
clinical development and advanced real-world evidence strategies that
can be embedded in the development process.

Identifying blood-based biomarkers for IBD has traditionally been
extremely difficult to do. The site of disease is the gut, which is a
complex tissue, composed of multiple cell types, whose relation to blood
in unclear.

“The overall results were impressive in their clarity and output” said
Professor Shai Shen-Orr, PhD., Chief Scientist at CytoReason and
Director of the Systems Immunology & Precision Medicine Lab in the
Faculty of Medicine at The Technion, Israel Institute of Technology. “We
demonstrated our ability to recreate and separate out cellular
contributions from bulk tissue measurements, discovering a pretreatment
upregulated pathway uniquely in anti-TNFα non-responders. Furthermore,
we established a clear biomarker relationship between biopsy and blood,
which we were able to validate with high accuracy.”

“With more than a decade of research behind our unique platform, I am
delighted to further demonstrate our ability to uncover critical
immunological insights, vital to R&D teams in the discovery, validation
and development of targets and the mitigation of clinical development
risks”, remarked David Harel, President and Chairman of CytoReason.
“This is exciting news for drug developers, who can use our unique
approach to exquisitely define research directions. Ultimately, this is
great news for the millions of patients who rely on the discovery,
development and availability of innovative and effective new therapeutic
options.”

About CytoReason
Based on more than 10 years of research,
CytoReason’s technology uses a proprietary data and machine learning
model to reconstruct cellular information from bulk tissue, to train an
immune-specific NLP engine, and to integrate multi-omics data. The
company’s platform organizes and standardizes collaborators’ data (gene,
protein, cell, and microbiome) and integrates it into CytoReason’s
proprietary disease model to generate mechanistic understanding of the
immune system, leading to novel insights.

CytoReason’s technology has yielded 2 pending patents, 9
commercial and scientific collaborations and 14 peer reviewed
publications. Fully applicable to cancer immunotherapy, autoimmune,
neurodegenerative and infectious disease research, CytoReason is at the
cutting edge of society’s boldest attempts to improve health outcomes
through better understanding of the immune system.

Contacts

Company Media:
Michelle Chiera, +972 52-600-0446 (Cell)
Blonde
2.0 for CytoReason
michelle@blonde20.com